Annual report pursuant to Section 13 and 15(d)

Organization, Description of Business, Reverse Stock Split, Business Disposals, Offerings and Merger (Details)

v3.21.1
Organization, Description of Business, Reverse Stock Split, Business Disposals, Offerings and Merger (Details)
$ in Thousands
2 Months Ended 12 Months Ended
Mar. 15, 2021
USD ($)
Aug. 24, 2020
day
Mar. 22, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Nov. 02, 2020
shares
Oct. 28, 2020
shares
Jan. 09, 2019
shares
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Warrants to purchase common stock, issued (shares) | shares           94,092 94,000 31,000
Net loss       $ 8,001 $ 6,708      
Impairment of intangible assets       2,201 0      
Merger costs       539 117      
Accumulated deficit       172,425 164,424      
Net cash used in operating activities       5,371 8,660      
Cash and cash equivalents       $ 2,444 $ 3,880      
Subsequent event                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Proceeds from equity issued     $ 29,500          
Convertible Debt                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Conversion ratio   0.20            
Conversion threshold trading days | day   5            
Threshold percentage of stock price trigger   85.00%            
StemoniX | Private placement | Series C Preferred Stock | Subsequent event                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Maximum committed amount $ 2,000              
Cancer Genetics, Inc. | Stockholders of CGI | Subsequent event                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Ownership percentage, noncontrolling owners 22.00%              
Cancer Genetics, Inc. | StemoniX | Subsequent event                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Ownership percentage, parent 78.00%